Patents by Inventor Igor Astsaturov

Igor Astsaturov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods Of Treating Cancer With Transmembrane Protein 16F (TMEM16F) Inhibitors
    Publication number: 20240122922
    Abstract: Compositions comprising a TMEM16F inhibitor, an anti-cancer agent, and a pharmaceutically acceptable agent, and methods of treating of cancer comprising administering a TMEM16F inhibitor are provided herein.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 18, 2024
    Inventors: Igor Astsaturov, Edna Cukierman
  • EGFR/NEDD9/TGF-? interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
    Patent number: 10450613
    Abstract: Compositions and methods for the treatment and diagnosis of cancer are disclosed.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 22, 2019
    Assignee: Fox Chase Cancer Center
    Inventors: Igor Astsaturov, Erica A. Golemis, Ilya G. Serebriiskii, Louis M. Weiner
  • C-Myc as a biomarker for tumor sensitivity to treatment with RNA polymerase II inhibition
    Patent number: 10328050
    Abstract: Systems and methods for determining whether a cancer patient may respond to inhibition of RNA polymerase II as a treatment for the patient are provided. Inhibition of RNA polymerase II may be by way of chemotherapy with an agent such as triptolide, an analog of triptolide, or a prodrug form of triptolide. The cancer patient may be a pancreatic cancer patient, an ovarian cancer patient, a gastric cancer patient, or an esophageal cancer patient. The patient may have any cancer in which c-Myc is over-expressed or over-amplified.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 25, 2019
    Assignees: Institute For Cancer Research, NexusPharma, Inc.
    Inventors: Igor Astsaturov, Vladimir Khazak, Ilya Serebriiskii
  • C-MYC As A Biomarker For Tumor Sensitivity To Treatment With RNA Polymerase II Inhibition
    Publication number: 20180263955
    Abstract: Systems and methods for determining whether a cancer patient may respond to inhibition of RNA polymerase II as a treatment for the patient are provided. Inhibition of RNA polymerase II may be by way of chemotherapy with an agent such as triptolide, an analog of triptolide, or a prodrug form of triptolide. The cancer patient may be a pancreatic cancer patient, an ovarian cancer patient, a gastric cancer patient, or an esophageal cancer patient. The patient may have any cancer in which c-Myc is over-expressed or over-amplified.
    Type: Application
    Filed: May 14, 2018
    Publication date: September 20, 2018
    Inventors: Igor Astsaturov, Vladimir Khazak, Ilya Serebriiskii
  • Method of treating MYC-amplified tumors with RNA-polymerase II inhibitors
    Patent number: 9993458
    Abstract: Systems and methods for determining whether a cancer patient may respond to inhibition of RNA polymerase II as a treatment for the patient are provided. Inhibition of RNA polymerase II may be by way of chemotherapy with an agent such as triptolide, an analog of triptolide, or a prodrug form of triptolide. The cancer patient may be a pancreatic cancer patient, an ovarian cancer patient, a gastric cancer patient, or an esophageal cancer patient. The patient may have any cancer in which c-Myc is over-expressed or over-amplified.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: June 12, 2018
    Assignees: Institute For Cancer Research, NexusPharma, Inc.
    Inventors: Igor Astsaturov, Vladimir Khazak, Ilya Serebriiski
  • EGFR/NEDD9/TGF-BETA INTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
    Publication number: 20170002426
    Abstract: Compositions and methods for the treatment and diagnosis of cancer are disclosed.
    Type: Application
    Filed: June 2, 2016
    Publication date: January 5, 2017
    Inventors: Igor Astsaturov, Erica A. Golemis, Ilya G. Serebriiskii, Louis M. Weiner
  • C-MYC as a Biomarker for Tumor Sensitivity to Treatment with RNA Polymerase II Inhibition
    Publication number: 20160354339
    Abstract: Systems and methods for determining whether a cancer patient may respond to inhibition of RNA polymerase II as a treatment for the patient are provided. Inhibition of RNA polymerase II may be by way of chemotherapy with an agent such as triptolide, an analog of triptolide, or a prodrug form of triptolide. The cancer patient may be a pancreatic cancer patient, an ovarian cancer patient, a gastric cancer patient, or an esophageal cancer patient. The patient may have any cancer in which c-Myc is over-expressed or over-amplified.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Inventors: Igor Astsaturov, Vladimir Khazak, Ilya Serebriiski
  • Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer
    Patent number: 9101631
    Abstract: Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: August 11, 2015
    Assignees: Georgetown University, Fox Chase Cancer Center
    Inventors: Vladimir Ratushny, Erica A. Golemis, Ilya G. Serebriiskii, Louis M. Weiner, Igor Astsaturov, Andrew Godwin
  • EGFR/NEDD9/TGF-BETA INTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
    Publication number: 20130331294
    Abstract: Compositions and methods for the treatment and diagnosis of cancer are disclosed.
    Type: Application
    Filed: July 15, 2013
    Publication date: December 12, 2013
    Applicant: Fox Chase Cancer Center
    Inventors: Igor Astsaturov, Erica A. Golemis, Ilya G. Serebriiskii, Louis M. Weiner
  • Combination Therapy Based on SRC and Aurora Kinase Inhibition for the Treatment of Cancer
    Publication number: 20110281935
    Abstract: Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.
    Type: Application
    Filed: December 14, 2009
    Publication date: November 17, 2011
    Inventors: Vladimir Ratushny, Erica A. Golemis, Ilya G. Serebriiskii, Louis M. Weiner, Igor Astsaturov, Andrew Godwin
  • Combination Therapy for the Treatment of Cancer
    Publication number: 20110033461
    Abstract: Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.
    Type: Application
    Filed: March 12, 2009
    Publication date: February 10, 2011
    Inventors: Vladimir Ratushny, Erica Golemis, Igor Astsaturov, Iiya G. Serebriiskii, Louis M. Weiner
  • EGFR/NEDD9/TGF-BETA INTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
    Publication number: 20100239656
    Abstract: Compositions and methods for the treatment and diagnosis of cancer are disclosed.
    Type: Application
    Filed: May 10, 2010
    Publication date: September 23, 2010
    Inventors: Igor Astsaturov, Erica A. Golemis, Ilya G. Serebriiskii, Louis M. Weiner
  • Vaccines using high-dose cytokines
    Publication number: 20040223949
    Abstract: The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response.
    Type: Application
    Filed: October 21, 2003
    Publication date: November 11, 2004
    Applicant: Sunnybrook and Women's College Health Sciences Center Aventis Pasteur, Ltd.
    Inventors: Igor Astsaturov, Teresa Petrella, Mark DeBenedette, Neil Berinstein, David E. Spaner